IP Library Granted Patent US 7,211,266
Granted Patent B2
US 7,211,266 · App. 10/402,192 · Granted May 1, 2007

Bone graft substitute composition

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,211,266
App. No.
10/402,192
Granted
May 1, 2007
Kind
B2
Abstract

A composition includes calcium sulfate hemihydrate, stearic acid, an accelerant, and a mixing solution. The composition can be injected, e.g., through a needle, and is capable of setting, e.g., in vivo, in a relatively short period of time to a relatively high hardness.

Claims (22)

1. A kit, comprising:

a mixture comprising greater than 95 weight percent calcium sulfate hemihydrate coated with sucrose, about 0.1 to about 0.5 weight percent calcium sulfate dihydrate, and about 1.5 to about 2 weight percent of a binder selected from the group consisting of stearic acid, hydroxypropylmethylcellulose, and hydroxymethylcellulose; and an aqueous saline mixing solution.

2. A composition, comprising:

greater than 95 weight percent calcium sulfate hemihydrate;

about 0.1 to about 0.5 weight percent calcium sulfate dihydrate coated with sucrose;

about 1.5 to about 2 weight percent stearic acid; and

a aqueous saline mixing solution,

wherein the composition is capable of hardening to about 4 MPa within about 10 minutes.

3. The composition of claim 2 , wherein the composition is injectable.

4. The composition of claim 3 , wherein the composition is injectable through a 6 cm long, 11-gauge needle.

5. A composition, consisting essentially of:

greater than 95 weight percent calcium sulfate hemihydrate;

about 0.1 to about 0.5 weight percent calcium sulfate dihydrate coated with sucrose;

about 1.5 to about 2 weight percent of a binder selected from the group consisting of stearic acid, hydroxypropylmethylcellulose, and hydroxymethylcellulose;

and a aqueous saline mixing solution.

6. A method, comprising:

providing a mixture comprising:

>95 wt % of calcium sulfate hemihydrate;

about 0.1 to about 0.5 wt % of calcium sulfate dihydrate coated with sucrose;

and about 1.5 to about 2 wt % of stearic acid; and

contacting the mixture with a saline solution to form a composition.

7. The method of claim 6 , further comprising injecting the composition through a needle.

Assignments (2)
RELEASE OF SECURITY INTEREST Recorded Nov 19, 2020
From: MIDCAP FUNDING IV TRUST
To: SOLANA SURGICAL, LLC; ORTHOPRO, L.L.C.; WRIGHT MEDICAL GROUP N.V.; WRIGHT MEDICAL GROUP, INC.; BIOMIMETIC THERAPEUTICS CANADA, INC.; BIOMIMETIC THERAPEUTICS, LLC; BIOMIMETIC THERAPEUTICS USA, INC.; INBONE TECHNOLOGIES, INC.; ORTHOHELIX SURGICAL DESIGNS, INC.; TORNIER US HOLDINGS, INC.; TORNIER, INC.; TROOPER HOLDINGS INC.; WHITE BOX ORTHOPEDICS, LLC; WRIGHT MEDICAL CAPITAL, INC.; WRIGHT MEDICAL TECHNOLOGY, INC.; WRIGHT MEDICAL GROUP INTELLECTUAL PROPERTY, INC.
Reel/Frame 054480/0001 →
SECURITY INTEREST Recorded Jan 5, 2017
From: WRIGHT MEDICAL TECHNOLOGY, INC.
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 041257/0126 →